GlaxoSmithKline Sacking Employees Amidst Beijing Bribery Accusations

GlaxoSmithKline Sacking Employees Amidst Beijing Bribery Accusations
MaoNo / Pixabay

While the number of employees was not shared by the source of this report, its believed to be in double digits as the company investigates China’s bribery claims. The company has also increased the monitoring of employee expense claims in order to ferret out the offenders. The company has over 7,000 people working in the Middle Kingdom.

GlaxoSmithKline china probe

In a statement today, GlaxoSmithKline plc (NYSE:GSK) (LON:GSK) stated that it monitors employees expenses all over the world but has chosen to intensify the scrutiny in China since the Chinese launched a recent probe of Glaxo. “Where we have found potential issues, we are thoroughly reviewing them and have withheld incentive payments where appropriate,” the statement said.

Seth Klarman’s 2021 Letter: Baupost’s “Never-Ending” Hunt For Information

Baupost's investment process involves "never-ending" gleaning of facts to help support investment ideas Seth Klarman writes in his end-of-year letter to investors. In the letter, a copy of which ValueWalk has been able to review, the value investor describes the Baupost Group's process to identify ideas and answer the most critical questions about its potential Read More

The Chinese allege that through a combination of travel agencies, GlaxoSmithKline plc (NYSE:GSK) (LON:GSK) employees have held fake conferences and have distributed nearly $500 million to doctors, government officials and hospital administrators since 2007 using improper transfers from travel agencies. The company has admitted that some executives are probably guilty and has said repeatedly that it will cooperate with the government investigation.

While China only represents 2% of total revenues for GlaxoSmithKline plc (NYSE:GSK) (LON:GSK), the company has seen significant growth in the country over the last three years. While third quarter sales fell a whopping 61% year-over-year, the fourth quarter rebounded with an increase of 17% to $1.26 billion year-over-year.

Less than a year into his ascension to the head of Glaxo’s China operations, Herve Gisserot will now have to sort through some dirty laundry left by former chief Mark Reilly.

The end of the junket

Big Pharma’s problems are not limited to China with governments and regulators in numerous countries cracking down on bribery. At the end of last year, GlaxoSmithKline plc (NYSE:GSK) (LON:GSK) announced that it would cease payments to doctors who attend medical meetings in say, Bora Bora. Rarely, are these meetings where speakers are paid held in Haiti or a country that ends in “stan.”

Just two years ago, GlaxoSmithKline plc (NYSE:GSK) (LON:GSK) reached a settlement with the U.S. Department of Justice for $3 billion after pleading guilty to the illegal promotion of drugs and the withholding of drug safety data. With this settlement and admission of guilt, Glaxo also agreed to end the practice of paying salespeople based on the amount of prescriptions doctors write.

Updated on

While studying economics, Brendan found himself comfortably falling down the rabbit hole of restaurant work, ultimately opening a consulting business and working as a private wine buyer. On a whim, he moved to China, and in his first week following a triumphant pub quiz victory, he found himself bleeding on the floor based on his arrogance. The same man who put him there offered him a job lecturing for the University of Wales in various sister universities throughout the Middle Kingdom. While primarily lecturing in descriptive and comparative statistics, Brendan simultaneously earned an Msc in Banking and International Finance from the University of Wales-Bangor. He's presently doing something he hates, respecting French people. Well, two, his wife and her mother in the lovely town of Antigua, Guatemala. <i>To contact Brendan or give him an exclusive, please contact him at [email protected]</i>
Previous article 3D Systems To Bring 3D-Printed Modules For Google’s Ara Next Year
Next article Why Tesla Has Fewer Paint Choices – Or Does It?

No posts to display